DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Efficacy and Safety of PerioChip Plus (Flurbiprofen/Chlorhexidine) Formulation in the Therapy of Adult Periodontitis

Information source: Dexcel Pharma Technologies Ltd.
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Periodontitis

Intervention: flurbiprofen/chlorhexidine (Drug)

Phase: Phase 2

Status: Not yet recruiting

Sponsored by: Dexcel Pharma Technologies Ltd.

Official(s) and/or principal investigator(s):
Aubrey Soskolne, Professor, Principal Investigator, Affiliation: Hadassah Medical Organization IRB

Overall contact:
Aubrey Soskolne, Professor, Phone: 972-2-6777826, Email: sosko@cc.huji.ac.il

Summary

To determine the effect of the placement of a PerioChip Plus (flurbiprofen/chlorhexidine -

FBP/CHX) formulation versus PerioChip (chlorhexidine) formulation versus Flurbiprofen Chip formulation versus Placebo Chip formulation on probing pocket depth (PPD)

Clinical Details

Official title: The Efficacy and Safety of PerioChip Plus (Flurbiprofen/Chlorhexidine) Formulation in the Therapy of Adult Periodontitis

Study design: Treatment, Randomized, Double-Blind, Active Control, Crossover Assignment, Safety/Efficacy Study

Primary outcome: At 24 weeks, relative to baseline, the mean reductions in probing pocket depth (PPD) will be used as primary efficacy endpoint. Additional primary endpoints are clinical attachment levels (CAL) and bleeding on probing (BOP) in the target pockets selected

Secondary outcome: PPD measurements at 6, 12 and 18 weeks will be used as secondary endpoints. Additional secondary endpoints are clinical attachment levels (CAL) and bleeding on probing (BOP) in the target pockets selected at screening, measured at weeks 6, 12 and 18.

Detailed description: This is an 80 subjects, single-center, randomized, double-blinded, parallel, 4-arm clinical study (25 subjects in the PerioChip Plus and PerioChip arms and 15 subjects in the Flurbiprofen Chip and Placebo Chip arms).

At 24 weeks, relative to baseline, the mean reductions in probing pocket depth (PPD) will be used as primary efficacy endpoint. Additional primary endpoints are clinical attachment levels (CAL) and bleeding on probing (BOP) in the target pockets selected at screening, measured at weeks 24.

PPD measurements at 6, 12 and 18 weeks will be used as secondary endpoints. Additional secondary endpoints are clinical attachment levels (CAL) and bleeding on probing (BOP) in the target pockets selected at screening, measured at weeks 6, 12 and 18.

Eligibility

Minimum age: 25 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Signed informed consent form

- Good general health

- Male or female subjects aged >25 years old

- Minimum of 8 natural teeth

- Availability for the 25 weeks duration of the study

- Periodontal disease on a natural teeth characterized by the presence of at least 2

teeth with periodontal pockets of 6-9 mm in depth (target teeth) in order to reach baseline (day 1) with periodontal pockets of 5-8 mm in depth, without involving the apex of the tooth.

- Females of childbearing potential must be non pregnant at entry and agree to use an

adequate method of birth control during the study.

- Demonstrate bleeding on probing to the base of the pocket at the pockets (sites)

selected at the time of screening.

Exclusion Criteria:

- Presence of oral local mechanical factors that could (in the opinion of the

investigator) influences the outcome of the study.

- Presence of orthodontic appliances or any removable appliance that impinges on the

tissues being assessed.

- Soft or hard tissue tumours of the oral cavity.

- Presence of dental implant adjacent to target tooth.

- Periodontal pockets of more than 9 mm in depth.

- General systemic antibiotics therapy or periodontal/mechanical/local delivery therapy

within 6 weeks prior to study entry and through out the study duration.

- History of allergy to chlorhexidine, flurbiprofen or to other non-steroidal

anti-inflammatory drugs (NSAIDs).

- Subjects taking diphenylhydantoin, nifedepine and/or cyclosporine, which might

influence the pattern of tissue response.

- Subject treated with non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days

prior to entry into the study and through out the study duration.

- Pregnant women or those planning to become pregnant or lactating women.

- Presence of the following conditions: Type 1 diabetes, major recurrent aphtae,

stomatitis and related oral pathologies.

- The presence of any medical or psychiatric condition or any other condition that in

the opinion of the investigator could affect the successful participation of the subject in the study.

- Subject participates in any other clinical study 30 days prior to the start of the

study and through out the study duration.

- Subject uses chlorhexidine oral rinses/ mouthwashes on a regular basis.

Locations and Contacts

Aubrey Soskolne, Professor, Phone: 972-2-6777826, Email: sosko@cc.huji.ac.il

Hadassah Medical Organization, Jerusalem 91120, Israel
Additional Information


Last updated: January 21, 2007

Page last updated: October 19, 2009

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014